Methods for treating lysosomal acid lipase deficiency in patients
AssigneeSynageva BioPharma Corp.
InventorAnthony Quinn
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.
Claims32
A method of treating a human patient suffering from a lysosomal acid lipase (LAL) deficiency, comprising administering a recombinant human LAL to said human patient in an amount effective to reduce the serum or blood level of a liver transaminase to a normal level, wherein the recombinant human LAL is administered between one time about every 7 days and one time about every 30 days and the administration is sufficient to reduce liver damage of said human patient.
Dependencies are inferred from the claim text.